Serum levels of osteoprotegerin and receptor activator of nuclear factor-κB ligand as markers of periprosthetic osteolysis

Journal of Bone and Joint Surgery

Volumn 88, Issue 7, 2006, Pages 1501-1509

  Granchi, Donatella ^a   Pellacani, Andrea ^a   Spina, Mauro ^a   Cenni, Elisabetta ^a   Savarino, Lucia Maria ^a   Baldini, Nicola ^a   Giunti, Armando ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYMATIC ASSAY; FEMALE; GENDER; HIP OSTEOARTHRITIS; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS FAILURE; PROSTHESIS LOOSENING; SKELETON; TOTAL HIP PROSTHESIS;

EID: 33745713044     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.E.01038     Document Type: Article

References (28)

1. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, Blair SN, Berman BM, Fries JF, Weinberger M, Lorig KR, Jacobs JJ, Goldberg V. Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med. 2000;133:726-37.
2. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001;142:5050-5.
3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-42.
4. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, Findlay DM. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br. 2001;83:902-11.
5. Clohisy JC, Frazier E, Hirayama T, Abu-Amer Y. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. J Orthop Res. 2003;21:202-12.
6. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials. 2004;25:565-73.
7. Clohisy JC, Hirayama T, Frazier E, Han SK, Abu-Amer Y. NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis. J Orthop Res. 2004;221:13-20.
8. Granchi D, Ciapetti G, Amato I, Pagani S, Cenni E, Savarino L, Avnet S, Peris JL, Pellacani A, Baldini N, Giunti A. The influence of alumina and ultra-high molecular weight polyethylene particles on osteoblast-osteoclast cooperation. Biomaterials. 2004;25:4037-45.
9. Granchi D, Amato I, Battistelli L, Ciapetti G, Pagani S, Avnet S, Baldini N, Giunti A. Molecular basis of osteoclastogenesis induced by osteoblasts exposed to wear particles. Biomaterials. 2005;26:2371-9.
10. Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin-clinical relevance and potential applications. Eur J Endocrinol. 2001;145:681-3.
11. Khosla S, Arrighi HM, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL. Correlates of osteoprotegerin levels in women and men. Osteoporos Int. 2002;13:394-9.
12. Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F, Heymann D. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol. 2003;163:2021-31.
13. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005;90:6323-31.
14. Sudanese A, Toni A, Busanelli L, Furno A, Montina PP, Marraro MD, Terzi S, Giunti A. Diagnostic protocol in prosthetic loosening. Chir Organi Mov. 1994;79:257-67.
15. Savarino L, Baldini N, Tarabusi C, Pellacani A, Giunti A. Diagnosis of infection af tertotal hip replacement. J Biomed Mater Res B Appl Biomater. 2004;70:13945.
16. Gruen TA, McNeice GM, Amstutz HC. "Modes of failure" of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop Relat Res. 1979;141:17-27.
17. DeLee JG, Charnley J. Radiological demarcation of cemented sockets in total hip replacement. Clin Orthop Relat Res. 1976;121:20-32.
18. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ. 2003;326:41-4.
19. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323:157-62.
20. Ritchlin CT, Schwarz EM, O'Keefe RJ, Looney RJ. RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskel Neuronal Interact. 2004;4:276-84.
21. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum. 2002;46:1744-53.
22. Trofimov S, Pantsulaia I, Kobyliansky E, Livshits G. Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/ macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol. 2004;150:305-11.
23. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999;14:518-27.
24. Lajeunesse D. The role of bone in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2004;12 Suppl A:S34-8.
25. Pulsatelli L, Dolzani P, Silvestri T, Caraceni P, Facchini A, Ravaglia G, Salvarani C, Meliconi R, Mariani E. Soluble receptor activator of nuclear factor-kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases. Biogerontology. 2004;5:119-27.
26. Bizot P, Nizard R, Hamadouche M, Hannouche D, Sedel L. Prevention of wear and osteolysis: alumina-on-alumina bearing. Clin Orthop Relat Res. 2001;393:85-93.
27. Rho J, Takami M, Choi Y. Osteoimmunology: interactions of the immune and skeletal systems. Mol Cells. 2004;17:1-9.
28. Savarino L, Granchi D, Cenni E, Baldini N, Greco M, Giunti A. Systemic cross-linked N-terminal telopeptide and procollagen I C-terminal extension peptide as markers of bone turnover after total hip arthroplasty. J Bone Joint Surg Br. 2005;87:571-6.